Samsung Pharmaceutical Co., Ltd. acquired Shinhwa IM Co., Ltd. for KRW 3.7 billion.
February 12, 2015 at 11:00 pm
Share
Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) acquired Shinhwa IM Co., Ltd. for KRW 3.7 billion on February 13, 2015. Under the terms of the deal, 0.05 million shares were acquired and payment were made with issued convertible bond of Samsung Pharmaceutical. For the period ended 2014, Shinhwa IM Co., Ltd. had total assets of KRW 1.52 billion, total stockholders' equity of KRW 1.06 billion, sales revenue of KRW 2.87 billion and net profit of KRW 182 million. The transaction was resolved by Board of Directors of Samsung Pharmaceutical on February 13, 2015.
Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) completed the acquisition of Shinhwa IM Co., Ltd. on February 13, 2015.
SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.